NPPA fixes retail price of 14 combo drugs including Aspirin, Paracetamol, Vitamin D3; Details

New Delhi: Through a recent notification, the government regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 14 drug formulations under the Drugs Prices Control Order (DPCO), 2013 exclusive of goods and services tax (GST).

The drugs whose price have been fixed by NPPA include Atorvastatin, Vitamin D3 Tablet, Rosuvastatin, Aspirin, Paracetamol in combination with other formulations. Some of the combinations are Paracetamol + Mefenamic Acid Suspension; Clopidogrel + Aspirin Tablet; Atorvastatin + Vitamin D3 Tablet; Metoprolol+ + Amlodipine Tablet and so on.

Notable drugmakers namely, Sun Pharmaceuticals Ltd (Sun Pharma), Intas Pharma, Cipla, Abbott, Mylan and others are responsible for manufacturing these widely used formulations.

Combination of Atorvastatin + Vitamin D3 Tablet manufactured by Sun Pharma is sold under the brand name Daztor. The product is indicated for the treatment of high cholesterol.

While another popular combination of Paracetamol + Mefenamic Acid Suspension manufactured and marketed under the brand name Mifucet by Intas Pharma is used for pain relief and treating fever.

The list also reads Sun Pharma's combination drug Clopidogrel + Aspirin Tablet sold as Clopilet A 75 Capsule which is used for the treatment of angina pectoris (chest discomfort/pain caused due to insufficient oxygen supply to the heart muscle), heart attack, and stroke (a medical condition caused by insufficient blood flow and oxygen supply to the brain).

The details of the list of all 14 formulations read;

The NPPA notice further adds;

• The manufacturer of above-mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.


• The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.


• The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.


• As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.


• The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.


• In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.


• Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

Also Read: NPPA fixes retail price of 18 commonly used formulations including Metformin, Atorvastatin; Details